4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat
4SC AG and Yakult Honsha Co.; Ltd. announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of resminostat in Japan. Resminostat, an oral, pan-histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by 4SC in hepatocellular carcinoma (HCC), Hodgkin lymphoma (HL) and colorectal cancer in KRAS-mutant patients (CRC). Yakult Honsha will develop and commercialise resminostat primarily in HCC, CRC and retains the rights to develop and commercialise resminostat in other oncology indications in Japan.
4SC will receive an upfront payment from Yakult Honsha of EUR6 million and up to EUR127 million payable upon achieving specified milestones including clinical and regulatory events in Japan. In addition to milestone payments, Yakult will pay 4SC double-digit royalties linked to product sales of resminostat, which will also include the API costs. 4SC will be the exclusive supplier of resminostat to Yakult Honsha. Yakult Honsha will be responsible for all development and clinical requirements in Japan for resminostat in HCC, CRC and other chosen oncology indications.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Horizon Discovery Joins 4D Cell Fate Consortium - Contributes rAAV-mediated genome editing technology to EU FP7 funded project aimed at understanding hES cell differentiation control
Charles River Laboratories Buys Inveresk - Create a Leading Global Partner to the Pharmaceutical and Biotechnology Industry

Looking for Start-up (ideas) in chemical engineering, chemistry and biotechnology - ACHEMA Start-Up Award
Innovative Roche cancer medicine Avastin approved in EU - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer

Researchers develop nanoscale probes for ssDNA sustainability under UV radiation
Zebrafish may offer researchers powerful new tool for studying innate immunity
Horizon Discovery appoints new CEO
ImmunoGen, Inc. Receives Patent on Production of DM1
Breast cancer: finding the smoking gun - A new method developed at Vanderbilt may help “inventory” all tumor-promoting genes.
Category:Orphan_drugs
